View source for Company:Roche

{{short description|Swiss multinational healthcare company}}
{{coord|47.558624|7.606018|display=title}}
{{Infobox company
| name = Roche Holding AG
| logo = Hoffmann-La Roche logo.svg
| image = Basel - Roche Tower - 19. April 2015.jpg
| image_size = 250px
| image_caption = The Roche Tower, headquarters of Hoffmann-La Roche in [[Place:Basel|Basel]] (2015).
| type = [[Finance:Aktiengesellschaft|Aktiengesellschaft]]
| traded_as = {{SWX|ROG}}
| ISIN = {{ISIN|sl=n|pl=y|CH0012032048}}
| foundation = {{start date and age|1896}}
| founder = Fritz Hoffmann-La Roche
| location = [[Place:Basel|Basel]], {{wipe|Switzerland}}
| key_people = {{unbulleted list|Severin Schwan {{small|(Chairman)}}|André Hoffmann {{small|(Vice-Chairman)}}|Thomas Schinecker {{small|([[Social:Chief executive officer|CEO]])}}|Teresa Graham {{small|(CEO, Pharmaceuticals)}}|Matt Sause {{small|(CEO, Diagnostics)}}|Levi Garraway {{small|CMO}}<ref>{{cite news |url=http://www.biopharminternational.com/fda-grants-roche-breakthrough-therapy-designation-hemophilia-drug |title=FDA Grants Roche Breakthrough Therapy Designation on Hemophilia Drug |date=19 April 2018 |access-date=2018-04-20 |work=BioPharm International |last=<!--no byline--> |publisher=UBM }}</ref><ref name="execcom">{{cite web|title=Executive Committee|url=https://www.roche.com/about/leadership/|website=Roche.com|publisher=F. Hoffmann-La Roche|access-date=18 April 2023}}</ref><ref>{{Cite news | url=https://www.reuters.com/business/healthcare-pharmaceuticals/roche-names-new-ceo-with-schwan-set-become-chairman-2022-12-12/ | title=Roche names new head of $13 billion diagnostics unit| work=Reuters| date=12 December 2022}}</ref>}}
| industry = [[Medicine:Pharmaceutical industry|Pharmaceutical]]s
| products = [[Chemistry:Pharmaceutical|Pharmaceutical]]s and [[Medicine:Medical diagnosis|diagnostics]] <small>(List of products)</small>
| revenue = {{nowrap|{{increase}} {{CHF|66.43 billion|link=yes}}}}
| revenue_year = 2022
| operating_income = {{nowrap|{{Decrease}} {{CHF|17.48 billion}}}}
| income_year= 2022
| net_income = {{nowrap|{{Decrease}} {{CHF|13.53 billion}}}}
| net_income_year = 2022
| assets = {{nowrap|{{Decrease}} {{CHF|88.15 billion}}}}
| assets_year = 2022
| equity = {{nowrap|{{Increase}} {{CHF|32.02 billion}}}}
| equity_year = 2022
| num_employees = {{Increase}} 103,613
| num_employees_year = 2022 
| parent = Roche Holding AG
| subsid = [[Company:Genentech|Genentech]], Ventana
| homepage = {{URL|www.roche.com}}
| footnotes = <ref name="FR22">{{cite web |url=https://assets.cwp.roche.com/f/126832/x/8971737b76/fb22e.pdf |title=Finance Report 2021 |date=4 February 2022 |access-date=1 April 2023 |publisher=Roche Holding}}</ref>
}}
[[File:F. Hoffmann-LaRoche & Co AG 1932.jpg|thumb|Participation certificate of the F. Hoffmann-LaRoche & Co AG, issued 15 January 1932]]

'''F. Hoffmann-La Roche AG''', commonly known as '''Roche''', is a {{wipe|Switzerland}} [[Finance:Multinational corporation|multinational]] healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its [[Social:Holding company|holding company]], '''Roche Holding AG''', has [[Finance:Share|shares]] listed on the SIX Swiss Exchange. The company headquarters are located in [[Place:Basel|Basel]]. 
Roche is the fifth-largest pharmaceutical company in the world by revenue<ref>{{Cite web|url=https://fortune.com/2022/08/15/global-500-biggest-pharma-companies/|title=The world's 10 biggest pharmaceutical companies raked in over $700 billion in revenue in 2021|website=Fortune |date=15 August 2022 |last=McGlauflin |first=Paige |archive-url=http://archive.today/2022.08.17-173918/https://fortune.com/2022/08/15/global-500-biggest-pharma-companies/ |archive-date=17 August 2022 |url-access=subscription}}</ref> and the leading provider of [[Medicine:Cancer|cancer]] treatments globally.<ref>{{Cite web|url=https://www.marketresearchreports.com/blog/2019/05/17/top-10-oncology-pharma-companies-world|title=Top 10 Oncology Pharma Companies in the World &#124; Market Research Blog|date=17 May 2019|website=Market Research Reports® Inc.}}</ref><ref>{{Cite web|url=http://www.pmlive.com/top_pharma_list/oncology_revenues|title=Top 20 pharma companies by oncology sales - Top Pharma List - PMLiVE|date=16 June 2014|website=pmlive.com}}</ref>

The company controls the American [[Engineering:Biotechnology|biotechnology]] company [[Company:Genentech|Genentech]], which is a wholly owned affiliate, and the Japanese biotechnology company [[Company:Chugai Pharmaceutical Co.|Chugai Pharmaceuticals]], as well as the United States-based companies Ventana and [[Organization:Foundation Medicine|Foundation Medicine]]. Roche's revenues during fiscal year 2020, were 58.32 billion Swiss francs. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm [[Company:Novartis|Novartis]] owning a further third of its shares until 2021. Roche is one of the few companies increasing their dividend every year, for 2020 as the 34th consecutive year.

F. Hoffmann-La Roche is a full member of the [[Organization:European Federation of Pharmaceutical Industries and Associations|European Federation of Pharmaceutical Industries and Associations]] (EFPIA).<ref>{{cite news|url=http://www.efpia.eu/content/default.asp?PageID=559&DocID=4883 |title=The Pharmaceutical Industry in Figures – 2008 Edition |publisher=European Federation of Pharmaceutical Industries and Associations (EFPIA) |page=49 |access-date=2008-08-25 |url-status=dead |archive-url=https://web.archive.org/web/20080916100937/http://www.efpia.eu/content/default.asp?PageID=559&DocID=4883 |archive-date=16 September 2008 |df=dmy-all }}</ref>

==History==
Founded in 1896 by Fritz Hoffmann-La Roche, the company was early on known for producing various vitamin preparations and derivatives.<ref>{{Cite news |title=Switzerland's Biggest Family Fortune Has Prospered for 124 Years |url=https://www.bloomberg.com/news/features/2020-08-06/switzerland-s-biggest-family-fortune-has-prospered-for-124-years |access-date=2022-03-16 |newspaper=Bloomberg.com|date = 6 August 2020}}</ref> In 1934, it became the first company to mass-produce synthetic [[Biology:Vitamin C|vitamin C]], under the brand name [[Chemistry:Redoxon|Redoxon]]. During the Second World War, Roche collaborated with the Nazi regime in Germany and used forced labour in its German and Polish-based factories.<ref>{{Cite web|url=https://www.swissinfo.ch/eng/chemical-firms-exploited-nazi-links--probe-found/2218350|title = Chemical firms exploited Nazi links, probe found}}</ref> They also moved all their Jewish employees to the United States to save them from Nazi attention.<ref>[https://www.latimes.com/archives/la-xpm-2005-oct-01-me-sternbach1-story.html Leo Sternbach, 97; Invented Valium, Many Other Drugs by THOMAS H. MAUGH II OCT. 1, 2005 L.A. Times]</ref>

In 1957, Hoffmann-La Roche introduced the class of tranquilizers known as [[Chemistry:Benzodiazepine|benzodiazepine]]s (with [[Chemistry:Diazepam|Valium]] and [[Chemistry:Flunitrazepam|Rohypnol]] being the best known members).<ref>{{Cite web |last=HannahBlake |date=2012-11-01 |title=A history of Roche |url=https://pharmaphorum.com/articles/a_history_of-_roche/ |access-date=2022-03-16 |website=pharmaphorum.com |language=en-GB}}</ref> It manufactures and sells several cancer drugs and is a leader in this field. In 1956, the first antidepressant, [[Chemistry:Iproniazid|iproniazid]], was accidentally created during an experiment while synthesizing [[Chemistry:Isoniazid|isoniazid]]. Originally, it had been intended to create a more efficient drug at combatting [[Medicine:Tuberculosis|Tuberculosis]]. Iproniazid, however, was revealed to have its own benefits; some people felt it made them feel happier. It was withdrawn from the market in the early 1960s due to toxic side-effects.

In 1976, an accident at a chemical factory in Seveso, Italy, owned by a subsidiary of Roche, caused a large [[Chemistry:Polychlorinated dibenzodioxins|dioxin]] contamination. In 1982, the United States arm of the company acquired Biomedical Reference Laboratories for US$163.5 million. That company dated from the late 1960s, and was located in Burlington, North Carolina. That year Hoffmann-La Roche then merged it with all of its laboratories, and incorporated the merged company as Roche Biomedical Laboratories, Inc. in Burlington. By the early 1990s, Roche Biomedical became one of the largest clinical laboratory networks in the United States, with 20 major laboratories and US$600 million in sales.<ref name="fundingroche">{{cite web|url=http://www.fundinguniverse.com/company-histories/Roche-Biomedical-Laboratories-Inc-Company-History.html|title=Roche Biomedical Laboratories, Inc|publisher= FundingUniverse.com}}</ref>

Roche has also produced various HIV tests and antiretroviral drugs. It bought the patents for the [[Biology:Polymerase chain reaction|polymerase chain reaction]] (PCR) technique in 1992. In 1995, the era of highly active anti-retroviral therapy (HAART) was initiated by the United States FDA's approval of Hoffman LaRoche's HIV protease inhibitor, saquinavir. Within 2 years of its approval (and that of ritonavir 4 months later) annual deaths from AIDS in the United States fell from over 50,000 to approximately 18,000. <ref>{{Cite web  | title = HIV Surveillance --- United States, 1981—2008 | url = https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6021a2.htm | access-date = 8 November 2013 }}</ref> On 28 April 1995, Hoffmann-La Roche sold Roche Biomedical Laboratories, Inc. to National Health Laboratories Holdings Inc. (which then changed its name to Laboratory Corporation of America Holdings).<ref name="sec950515">[http://www.secinfo.com/ds2yr.a4.htm Laboratory Corp of America Holdings · 10-Q · For 3/31/95], SECInfo.com, Filed On 5/15/95, SEC File 1-11353, Accession Number 920148-95-11</ref> Roche acquired Syntex in 1994, and Chugai Pharmaceuticals in 2002.

[[Chemistry:Oseltamivir|Oseltamivir]] an antiviral drug used to combat influenza. Roche is the only drug company authorized to manufacture the drug, which was discovered by [[Company:Gilead Sciences|Gilead Sciences]].  Roche purchased the rights to the drug in 1996, and in 2005, settled a royalty dispute, agreeing to pay Gilead tiered royalties of 14–22% of annual net sales without adjusting the payments for manufacturing costs, as had been allowed in the original licensing agreement.<ref name="royalty">{{cite news|url=http://www.redherring.com/Article.aspx?a=14507&hed=Roche%2C+Gilead+End+Tamiflu+Feud
|work=Red Herring|title=Roche, Gilead End Tamiflu Feud|date=16 November 2005}}</ref>

On 20 October 2005, Hoffmann-La Roche decided to license other companies to manufacture [[Chemistry:Oseltamivir|Oseltamivir]].<ref>{{cite magazine|url=http://www.time.com/time/business/article/0,8599,1120533,00.html|archive-url=https://web.archive.org/web/20051022133611/http://www.time.com/time/business/article/0,8599,1120533,00.html|url-status=dead|archive-date=22 October 2005|title=Why Roche Released Tamiflu|access-date=2008-05-22|last=Kher|first=Unmesh|date=2005-10-19|magazine=Time}}</ref>

Also in 2005, Roche acquired the Swiss company GlycArt Biotechnology in order to acquire technology to [[Chemistry:Afucosylated monoclonal antibodies|afucosylate antibodies]]; one of its products in development was [[Chemistry:Obinutuzumab|obinutuzumab]], which gained FDA approval in November 2013 for the treatment of [[Medicine:Chronic lymphocytic leukemia|chronic lymphocytic leukemia]].<ref name="roche">{{cite web |url=http://www.roche.com/media/store/releases/med-cor-2005-07-19.htm |archive-url=https://web.archive.org/web/20150205033013/http://www.roche.com/media/store/releases/med-cor-2005-07-19.htm |url-status=dead |archive-date=5 February 2015 |title=Roche - Roche acquires Swiss based GlycArt Biotechnology to strengthen expertise in therapeutic antibody research |publisher=roche.com |access-date=2015-04-29 |df=dmy-all }}</ref><ref>[https://web.archive.org/web/20160305002757/https://ec.europa.eu/research/health/pdf/event04/joel-jean-mairet-31032011_en.pdf Presentation: GlycArt Biotechnology AG From Inception to trade sale – and what happened after...] by Dr. Joël Jean-Mairet. Brussels, March 31, 2011</ref><ref name=2014reviewCameron>{{cite journal | last1 = Cameron | first1 = F | last2 = McCormack | first2 = PL | date = Jan 2014 | title = Obinutuzumab: first global approval | journal = Drugs | volume = 74 | issue = 1| pages = 147–54 | pmid = 24338113 | doi = 10.1007/s40265-013-0167-3 | s2cid = 40983655 }}</ref>

On 22 January 2008, Roche acquired Ventana Medical Systems for $3.4 billion.<ref>{{cite web|title=Roche buys Ventana|url=http://www.roche.com/media/media_releases/med-cor-2008-01-22.htm|access-date=2 June 2014|url-status=dead|archive-url=https://web.archive.org/web/20140605051428/http://www.roche.com/media/media_releases/med-cor-2008-01-22.htm|archive-date=5 June 2014|df=dmy-all}}</ref> On 2 January 2009,  Roche acquired Memory Pharmaceuticals Corp.<ref>{{cite news|title=Roche buys Memory Pharmaceuticals |url=https://www.nytimes.com/2009/03/13/business/worldbusiness/13drugs.html|access-date=2 June 2014 | work=The New York Times|first=Andrew|last=Pollack|date=12 March 2009}}</ref>

On 26 March 2009, Roche acquired [[Company:Genentech|Genentech]] for $46.8 billion.<ref>{{cite news|title=Roche buys Genentech |url=https://www.nytimes.com/2009/03/13/business/worldbusiness/13drugs.html|access-date=2 June 2014 | work=The New York Times|first=Andrew|last=Pollack|date=12 March 2009}}</ref> On 12 March 2009, Roche agreed to fully acquire Genentech, in which it had held a majority stake since 1990,<ref>{{cite news |url=https://www.nytimes.com/1990/02/05/business/genentech-roche-deal-may-spur-similar-ties.html |title=Genentech-Roche Deal May Spur Similar Ties |last=Pollack |first=Andrew |work={{wipe|The New York Times}} |date=5 February 1990 |access-date=2009-04-11}}</ref> after eight months of negotiations. As a result of the Genentech acquisition, Roche moved its Palo Alto based research facilities to their campus that straddles the border between Clifton, New Jersey and Nutley, New Jersey while Roche's United States headquarters, located on the New Jersey site since 1929, was moved to Genentech's facility in South San Francisco.<ref name=toltb>{{cite news |url=http://business.timesonline.co.uk/tol/business/industry_sectors/health/article5897691.ece |title=Roche swallows Genentech in third large drugs deal |last=Bawden |first=Tom |work=The Times |date=13 March 2009 |access-date=2009-04-11 | location=London|archive-url=https://web.archive.org/web/20110612124041/http://business.timesonline.co.uk/tol/business/industry_sectors/health/article5897691.ece|archive-date=2011-06-12 |url-status=dead}}</ref> Genentech became a wholly owned [[Social:Subsidiary|subsidiary]] group of Roche on 25 March 2009.<ref>{{cite news |url=https://www.reuters.com/article/mergersNews/idUSLQ73529820090326 |title=Roche completes Genentech buy |last=Jucca |first=Lisa |author2=Cage, Sam |work={{wipe|Reuters}} |date=26 March 2009 |access-date=2009-04-11}}</ref> Roche began vacating the NJ site in 2012, and sold it off in 2016.<ref>{{cite news |url=https://www.northjersey.com/story/news/essex/nutley/2017/06/15/ex-roche-campus-reinvented-on-3-science-center/393841001/ |title=Ex-Roche campus reinvented as 'On3' science center |last=Proctor |first=Owen |work=northjersey.com |date=17 June 2017 |access-date=2022-08-30}}</ref>

Roche acquired Medingo Ltd. in April 2010, for $160 million<ref>{{cite web|title=Roche buys Medingo|url=http://www.roche.com/investors/ir_update/inv-update-2010-04-13.htm|access-date=2 June 2014|url-status=dead|archive-url=https://web.archive.org/web/20140112213107/http://www.roche.com/investors/ir_update/inv-update-2010-04-13.htm|archive-date=12 January 2014|df=dmy-all}}</ref> and BioImagene, Inc. in August for $100 million.<ref>{{cite web|title=Roche buysBioImagene|url=http://www.roche.com/investors/ir_update/inv-update-2010-08-23.htm|access-date=2 June 2014|url-status=dead|archive-url=https://web.archive.org/web/20140605051034/http://www.roche.com/investors/ir_update/inv-update-2010-08-23.htm|archive-date=5 June 2014|df=dmy-all}}</ref>

In 2011, the company received the International Society for Pharmaceutical Engineering Facility of the Year Award for Process Innovation for Roche's "MyDose" Clinical Supply project.<ref>{{cite web |url=http://www.facilityoftheyear.org/foyawinners2011 |title=2011 Facility of the Year Category winners |access-date=2012-06-28}}</ref> In March 2011, Roche acquired PVT Probenverteiltechnik GmbH for up to €85 million.<ref>{{cite web|title=Roche buys PVT|url=http://www.roche.com/investors/ir_update/inv-update-2011-03-15.htm|access-date=2 June 2014|url-status=dead|archive-url=https://web.archive.org/web/20140605051430/http://www.roche.com/investors/ir_update/inv-update-2011-03-15.htm|archive-date=5 June 2014|df=dmy-all}}</ref> In July 2010, Roche acquired mtm laboratories AG for up to 190 million EUR.<ref>{{cite web|title=Roche buys mtm labs|url=http://www.roche.com/investors/ir_update/inv-update-2011-07-19.htm|access-date=2 June 2014|url-status=dead|archive-url=https://web.archive.org/web/20140605051033/http://www.roche.com/investors/ir_update/inv-update-2011-07-19.htm|archive-date=5 June 2014|df=dmy-all}}</ref> On October, Roche acquired Anadys Pharmaceuticals, Inc. for $230 million.<ref>{{cite web|title=Roche buys Anadys|url=http://www.roche.com/investors/ir_update/inv-update-2011-10-17.htm|access-date=2 June 2014|url-status=dead|archive-url=https://web.archive.org/web/20140605051030/http://www.roche.com/investors/ir_update/inv-update-2011-10-17.htm|archive-date=5 June 2014|df=dmy-all}}</ref> In December, Roche announced it would acquire Munich-based Verum Diagnostica GmbH, gaining entry to the fastest-growing field in the coagulation diagnostics market.<ref>{{cite web|url=https://www.biospace.com/article/roche-acquires-b-verum-diagnostica-gmbh-b-for-11-million-/|title=Roche Acquires Verum Diagnostica GmbH for €11 Million|website=BioSpace}}</ref>

On 26 June 2012, Roche announced the closure of the Nutley/Clifton campus, which was completed in 2013. The property is in the process of remediation.<ref>{{cite web|title=Roche announces closure of Nutley, NJ site|url=http://www.rocheusa.com/portal/usa/press_releases_nutley?siteUuid=re7180004&paf_gear_id=38400020&pageId=re7425113&synergyaction=show&paf_dm=full&nodeId=1414-483eca26c04011e1bf151d03aefa681a|access-date=28 June 2012|url-status=dead|archive-url=https://web.archive.org/web/20130518034353/http://www.rocheusa.com/portal/usa/press_releases_nutley?siteUuid=re7180004&paf_gear_id=38400020&pageId=re7425113&synergyaction=show&paf_dm=full&nodeId=1414-483eca26c04011e1bf151d03aefa681a|archive-date=18 May 2013|df=dmy-all}}</ref>

In July 2013, Roche Diagnostics acquired blood diagnostics company Constitution Medical Inc. for $220 million.<ref>{{cite web|title=Roche buys Constitution Medical|url=http://www.roche.com/investors/ir_update/inv-update-2013-07-02.htm|access-date=2 June 2014|url-status=dead|archive-url=https://web.archive.org/web/20140602200439/http://www.roche.com/investors/ir_update/inv-update-2013-07-02.htm|archive-date=2 June 2014|df=dmy-all}}</ref> Later, in September, Genentech announced it would acquire Arrayit Corporation.<ref>{{cite web|url=https://www.biospace.com/article/genentech-purchases-arrayit-corporation-technology-/|title=Genentech Purchases Arrayit Corporation Technology|website=BioSpace}}</ref>

On 7 April 2014, Roche announced its intention to acquire IQuum for up to $450 million,<ref>{{cite web|title=Roche buys IQuum|url=http://www.roche.com/investors/ir_update/inv-update-2014-04-07.htm|access-date=2 June 2014|url-status=dead|archive-url=https://web.archive.org/web/20140602195751/http://www.roche.com/investors/ir_update/inv-update-2014-04-07.htm|archive-date=2 June 2014|df=dmy-all}}</ref> as well as the rights to an experimental drug (ORY-1001) from Spanish company Oryzon Genomics for $21 million and up to $500 million in milestone payments.<ref>{{cite news|title=Roche buys experimental drug rights from Oryson |url=https://www.reuters.com/article/us-roche-oryzon-idUSBREA360KN20140407|access-date=2 June 2014 | work=Reuters|first=Caroline|last=Copley|date=7 April 2014}}</ref> On 2 June, Roche announced its intention to acquire Genia Technologies Inc. for up to $350 million.<ref>{{cite news|title=Roche buys Genia |url=https://www.bloomberg.com/news/2014-06-02/roche-agrees-to-buy-genia-technologies-for-up-to-350-million.html|access-date=2 June 2014 | work=Bloomberg|first=Thomas|last=Mulier|date=2 June 2014}}</ref> In August 2014, the company agreed to purchase Californian-based pharmaceutical firm InterMune for $8.3 billion, at $74 a share this represents a 38% premium over the final share closing price,<ref>{{cite news|url=https://www.bloomberg.com/news/2014-08-24/roche-holding-agrees-to-buy-intermune-for-8-3-billion.html|title=Roche Holding Agrees to Buy InterMune for $8.3 Billion|author=Michelle Cortez|date=24 August 2014|publisher=Bloomberg L.P.}}</ref><ref name="RocheInterMune">{{cite news|title=Roche pays 37% premium on shares for InterMune in US $8.3bn deal|url=http://www.sanfrancisconews.net/index.php/sid/225058355/scat/3a8a80d6f705f8cc|date=24 August 2014|access-date=24 August 2014|publisher=San Francisco News.Net}}</ref> as well as Santaris Pharma A/S for $450 million.<ref>{{cite web|url=https://www.biospace.com/article/roche-bags-santaris-pharma-a-s-in-deal-worth-450-million-/|title=Roche Bags Santaris Pharma A/S In Deal Worth $450 Million|website=BioSpace}}</ref> In December 2014, the company acquired next-generation sequencing processing company Bina Technologies for an undisclosed sum<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/roche-acquires-big-data-platform-provider/81250725/|title=Roche Acquires Big Data Platform Provider|work=GEN|date=19 December 2014}}</ref> and Dutalys GmbH<ref name="biospace.com">{{cite web|url=https://www.biospace.com/article/roche-to-pay-up-to-489-million-for-next-gen-antibody-firm-b-dutalys-b-/|title=Roche To Pay Up To $489 Million For Next-Gen Antibody Firm Dutalys|website=BioSpace}}</ref> a developer of next-generation anti-bodies.<ref name="biospace.com"/>

On 16 January 2015, the company announced that they would acquire Trophos for €470 million ($543 million) in order to increase the company's neuromuscular disease presence. The deal will centre on the Phase II and III [[Medicine:Spinal muscular atrophy|spinal muscular atrophy]] drug [[Chemistry:Olesoxime|olesoxime]] (TRO19622).<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/roche-to-buy-trophos-for-up-to-543m/81250813/|title=Roche to Buy Trophos for Up-to-$543M|work=GEN|date=16 January 2015}}</ref> In April 2015, Roche acquired CAPP Medical, and its chief development of technology for cancer screening and monitoring via the detection of circulating tumour DNA.<ref>{{cite web|url=https://www.biospace.com/article/roche-grabs-b-capp-medical-b-a-liquid-biopsy-startup-targeting-cancer-/|title=Roche Grabs CAPP Medical, a "Liquid Biopsy" Startup Targeting Cancer|website=BioSpace}}</ref>

In August, the company announced its intention to acquire GeneWEAVE, Inc. for up to $425 million in order to strengthen its microbial diagnostics business.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/roche-to-acquire-geneweave-for-up-to-425m/81251623/|title=Roche to Acquire GeneWEAVE for Up-to $425M|work=GEN|date=13 August 2015}}</ref> Days later the company acquired Kapa Biosystems, Inc. for $445M, focussing on next generation sequencing and polymerase chain reaction applications.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/roche-acquires-genomic-tools-provider-kapa-biosystems/81251641/|title=Roche Acquires Genomic Tools Provider Kapa Biosystems|work=GEN|date=19 August 2015}}</ref> In October 2015, the company acquired Adheron Therapeutics for $105 million (plus up to $475 million in milestone payments).<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/roche-to-acquire-adheron-therapeutics-for-105-upfront/81251839/|title=Roche to Acquire Adheron Therapeutics for $105 Upfront - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN|website=GEN|date=9 October 2015|access-date=23 May 2017}}</ref>

In January 2016, the company announced it would acquire Tensha Therapeutics for $115 million upfront, with $420 million in contingent payments.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/roche-acquires-tensha-therapeutics-for-115m-upfront/81252212/|title=Roche Acquires Tensha Therapeutics for $115M Upfront - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN|website=GEN|access-date=23 May 2017|date=11 January 2016}}</ref>

In January 2017, the company acquired ForSight VISION4.<ref>{{cite press release|url=http://www.prnewswire.com/news-releases/forsight-vision4-inc-announces-acquisition-by-roche-300388249.html|title=ForSight VISION4, Inc. Announces Acquisition by Roche|first=ForSight VISION4|last=Inc.|agency=PR Newswire}}</ref> In June, the company acquired the diabetes management platform, mySugr GmbH for an undisclosed price.<ref>{{cite news|url=https://uk.reuters.com/article/us-roche-diabetes-acquisition-idUKKBN19L0H9|title=Roche buys diabetes app firm in digital health push|first=John|last=Miller|work=Reuters|date=30 June 2017}}</ref> In November Roche acquired Viewics, Inc.<ref>{{cite web|url=https://www.biospace.com/article/roche-scoops-up-bay-area-s-viewics-amid-diagnostic-data-push/|title=Roche Scoops Up Bay Area's Viewics Amid Diagnostic Data Push|website=BioSpace}}</ref> In late December the company announced it would acquire Ignyta Inc, expanding its global oncology business.<ref>{{cite news|url=https://uk.reuters.com/article/us-ignyta-m-a-roche-idUKKBN1EG0HH|title=Roche to buy U.S. cancer drugmaker Ignyta for $1.7 billion|date=22 December 2017|work=Reuters.com|agency=Reuters}}</ref>

In February 2018, Roche announced it would acquire Flatiron Health, a business specialising in US cancer data analytics, for $1.9 billion.<ref>{{cite news|url=https://www.ft.com/content/f79d2cc0-1290-11e8-940e-08320fc2a277 |archive-url=https://ghostarchive.org/archive/20221210/https://www.ft.com/content/f79d2cc0-1290-11e8-940e-08320fc2a277 |archive-date=10 December 2022 |url-access=subscription|title=Roche pays $1.9bn for Alphabet-backed Flatiron Health|website=Financial Times|date=15 February 2018|last1=Dye|first1=Jessica}}</ref><ref>{{cite news|url=https://uk.reuters.com/article/uk-flatiron-health-m-a-roche-hldg-idUKKCN1FZ2R2|title=Roche to buy Flatiron Health for $1.9 billion to expand cancer care...|date=15 February 2018|work=Reuters.com|agency=Reuters}}</ref> In June of the same year the company announced it would acquire the outstanding shares of [[Organization:Foundation Medicine|Foundation Medicine]] for $2.4 billion ($137 per share).<ref>{{cite news|url=https://uk.reuters.com/article/us-roche-hldg-m-a-fmi-idUKKBN1JF0F3|title=Roche pays $2.4 billion for rest of cancer expert Foundation Medicine|date=19 June 2018|work=Reuters.com|agency=Reuters}}</ref> Later in September Roche announced its intention to acquire Tusk Therapeutics for up to €655 million ($759 million) expanding Roche's oncology pipeline. Tusk announced that the anti-CD38 antibody it is developing will be spun off to form a new company, Black Belt Therapeutics.<ref>{{cite web|url=https://www.genengnews.com/news/roche-acquires-cancer-immunotherapy-developer-tusk-therapeutics/|title=Roche Acquires Cancer Immunotherapy Developer Tusk Therapeutics|date=28 September 2018}}</ref> In late November, the company announced that Genentech would acquire Jecure Therapeutics, gaining access to Jecure's portfolio of [[Biology:NLRP3|NLRP3]] inhibitors developed to fight inflammatory diseases like non-alcoholic steatohepatitis and liver fibrosis.<ref>{{cite news|url=https://uk.reuters.com/article/us-jecure-m-a-roche-hldg-idUKKCN1NW23L|title=Roche buys U.S. biotech Jecure in race for liver disease drugs|date=27 November 2018|work=Reuters.com|agency=Reuters}}</ref>

In February 2019, the business announced it would acquire [[Biology:Gene therapy|gene therapy]] company, Spark Therapeutics, for {{US$|4.3 billion}} ($114.50 per share) adding Spark's gene therapy portfolio to its previous acquired assets. Spark has an already approved treatment for [[Medicine:Leber congenital amaurosis|Leber's congenital amaurosis]], Luxturna – priced at {{US$|850,000}} per patient.<ref>{{cite news|url=https://uk.reuters.com/article/us-spark-m-a-roche-hldg-idUKKCN1QE0L6|title=Roche 'steps up' for gene therapy with $4.3 billion Spark bet|date=25 February 2019|work=Reuters.com|agency=Reuters}}</ref> The offer to acquire Spark Therapeutics was extended to May 2019 after Roche was unable to garner majority support from Spark shareholders.<ref>{{cite web |title=Roche says its $4.3 billion offer for Spark is still on track for June completion |url=https://www.cnbc.com/2019/04/03/roche-says-its-4point3-billion-offer-for-spark-is-still-on-track-for-june-completion.html |publisher=CNBC |date=3 April 2019}}</ref>  A second gene therapy-related action came in December with the {{US$|1.15 billion}} acquisition of non-United States rights to an investigational [[Medicine:Duchenne muscular dystrophy|duchenne muscular dystrophy]] gene therapy developed by [[Company:Sarepta Therapeutics|Sarepta Therapeutics]].<ref>{{Cite news|url=https://www.reuters.com/article/us-roche-sarepta/roche-dives-deeper-into-gene-therapy-with-1-15-billion-sarepta-licensing-deal-idUSKBN1YR0G6|title=Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing deal|last1=Koltrowitz|first1=Silke|date=23 December 2019|access-date=24 December 2019|work=Reuters|last2=Nadeem|first2=Dania}}</ref>  In November, Roche acquired Promedior and its lead treatment – PRM-151 – for the treatment of [[Medicine:Idiopathic pulmonary fibrosis|idiopathic pulmonary fibrosis]], for $390 million upfront and another $1 billion in milestone payments.<ref>{{Cite web | url=https://www.biospace.com/article/roche-snaps-up-ipf-aimed-therapeutic-in-acquisition-of-promedior/?s=79 |title = Roche to Acquire Fibrosis-Focused Promedior for up to $1.4 Billion}}</ref><ref>{{Cite web | url=https://www.biospace.com/article/releases/promedior-enters-into-definitive-merger-agreement-to-be-acquired-by-roche/ |title = Promedior Enters into Definitive Merger Agreement to be Acquired by Roche}}</ref>

In March 2020, the [[Company:Roche Diagnostics|Roche Diagnostics]] division reached a significant milestone with the FDA-approval of its high-volume Sars-CoV-2 diagnostic test, capable of analysing 1,400-8,800 samples within 24h on the proprietary Cobas 6800/8800 molecular testing system.<ref>Hale C. (March 2020). [https://www.fiercebiotech.com/medtech/fda-grants-roche-coronavirus-test-emergency-green-light-within-24-hours "FDA grants Roche coronavirus test emergency green light within 24 hours"] ''FierceBiotech''. Retrieved 13 March 2020.</ref> In May the company announced it had acquired US-based Stratos Genomics for an undisclosed amount.<ref>{{Cite news | url=https://uk.reuters.com/article/us-roche-hldg-m-a-stratos/roche-buys-u-s-gene-sequencing-tech-company-stratos-genomics-idUKKBN22Y0MX |title = Roche buys U.S. Gene sequencing tech company Stratos Genomics|work = Reuters|date = 22 May 2020}}</ref><ref>{{Cite web | url=https://www.roche.com/media/releases/med-cor-2020-05-22b.htm | title=Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use}}</ref> In September, the business acquired Ireland-based Inflazome, for €380 million, gaining control of  its [[Biology:NLRP3|NLRP3]] [[Biology:Inflammasome|inflammasome]] inhibitors.<ref>{{Cite web|url=https://www.biospace.com/article/roche-dives-into-nlrp3-inflammasome-inhibition-with-acquisition-of-inflazome/|title=Roche Dives into NLRP3 Inflammasome Inhibition with Acquisition of Inflazome|website=BioSpace}}</ref><ref>{{Cite web|url=https://www.biospace.com/article/inflazome-announces-acquisition-by-roche/|title=Inflazome Announces Acquisition by Roche|website=BioSpace}}</ref>

In March 2021, Roche announced it would acquire GenMark Diagnostics for $1.8 billion.<ref>{{Cite web|url=https://www.biospace.com/article/roche-acquires-genmark-diagnostics-and-its-covid-19-test-in-1-8-billion-deal/?s=79|title = Roche Bolsters Diagnostics Pipeline with $1.8 Billion Buy of GenMark}}</ref><ref>[https://www.reuters.com/article/us-roche-genmark/roche-buys-genmark-for-1-8-million-to-challenge-test-rivals-idUSKBN2B70JH Reuters]</ref> Under the terms of agreement, Genmark  diagnostics will become a subsidiary and the principal operations will continue to remain in Carlsbad, California.<ref>{{Cite web|url=https://www.roche.com/media/releases/med-cor-2021-03-15b.htm|title=Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample}}</ref> In September, the company announced it would acquire German biotech group, TIB Molbiol, enhancing its molecular diagnostics operations.<ref>{{Cite news|url=https://www.reuters.com/article/tibmolbiol-m-a-roche-hldg/roche-holding-to-buy-tib-molbiol-to-enhance-molecular-diagnostics-idUSKBN2G50D1|title = Roche Holding to buy TIB Molbiol to enhance molecular diagnostics|work = Reuters|date = 9 September 2021}}</ref>

== Family ==

The Hoffmann-La Roche family is Switzerland's richest and one of the most secretive families.<ref>{{cite news | url=https://www.bloomberg.com/news/features/2020-08-06/switzerland-s-biggest-family-fortune-has-prospered-for-124-years | title=Switzerland's Biggest Family Fortune Has Prospered for 124 Years | newspaper=Bloomberg.com | date=6 August 2020 }}</ref> Many members of the family don't carry the last name Hoffmann anymore. Some are known as Oeri, Michalksi, Faber-Castell, Fabre, Schmid or Duschmalé.<ref>{{cite web | url=https://www.bzbasel.ch/basel/125-jahr-jubilaeum-nachkomme-und-verwaltungsrat-joerg-duschmale-roche-war-immer-da-seit-ich-ganz-klein-war-ld.2189054?reduced=true | title=Nachkomme und Verwaltungsrat Jörg Duschmalé: "Roche war immer da, seit ich ganz klein war" | date=18 September 2021 }}</ref>

===Acquisition history===
{{hidden begin|border=1px  #aaa solid|title=Roche Acquisitions|ta1=center}}
{{Tree list}}
*'''Hoffmann-La Roche''' <small>(Founded 1896 by Fritz Hoffmann-La Roche)</small>
**Biomedical Reference Laboratories <small>(Acq 1982, restructured into Roche Biomedical Laboratories, Inc in 1982, sold 1995)</small>
**Syntex <small>(Acq 1994)</small>
**Chugai Pharmaceuticals <small>(Acq 2002)</small>
**[[Company:454 Life Sciences|454 Life Sciences]] <small>(Acq 2007)</small>
**[[Company:Roche Diagnostics|Roche Diagnostics]]
***Spring BioScience Corp <small>(Acq 2007)</small>
***Ventana Medical Systems <small>(Acq 2009)</small>
***mySugr GmbH <small>(Acq 2017)</small>
***Viewics, Inc <small>(Acq 2017)</small>
***Flatiron Health <small>(Acq 2018)</small>
***Stratos Genomics <small>(Acq 2020)</small>
**Memory Pharmaceuticals Corp <small>(Acq 2009)</small>
**[[Company:Genentech|Genentech]] <small>(Acq 2009)</small>
***Tanox, Inc <small>(Acq 2006)</small>
***Arrayit Corporation <small>(Acq 2013)</small>
***Seragon <small>(Acq 2014)</small>
***Jecure Therapeutics <small>(Acq 2018)</small>
**Medingo Ltd <small>(Acq 2010)</small>
**BioImagene, Inc. <small>(Acq 2010)</small>
**PVT Probenverteiltechnik GmbH <small>(Acq 2010)</small>
**MTM laboratories AG <small>(Acq 2010)</small>
**Anadys Pharmaceuticals, Inc. <small>(Acq 2010)</small> 
**Verum Diagnostica GmbH <small>(Acq 2011)</small>
**Constitution Medical Inc. <small>(Acq 2012)</small>
**IQuum <small>(Acq 2014)</small>
**Genia Technologies Inc. <small>(Acq 2014)</small>
**InterMune <small>(Acq 2014)</small>
**Santaris Pharma A/S  <small>(Acq 2014)</small>
**Bina Technologies, Inc. <small>(Acq 2014)</small>
**Dutalys GmbH <small>(Acq 2014)</small>
**Ariosa Diagnostics <small>(Acq 2014)</small>
**Trophos <small>(Acq 2015)</small>
**CAPP Medical <small>(Acq 2015)</small>
**GeneWEAVE BioSciences, Inc. <small>(Acq 2015)</small>
**Kapa Biosystems, Inc. <small>(Acq 2015)</small>
**Adheron Therapeutics <small>(Acq 2015)</small>
**Tensha Therapeutics <small>(Acq 2016)</small>
**ForSight VISION4 <small>(Acq 2017)</small>
**Ignyta Inc <small>(Acq 2017)</small>
**[[Organization:Foundation Medicine|Foundation Medicine, Inc.]] <small>(Acq 2018)</small>
**Tusk Therapeutics <small>(Acq 2018)</small>
**Spark Therapeutics <small>(Acq 2019)</small>
**Promedior <small>(Acq 2019)</small>
**Stratos Genomics <small>(Acq 2020)</small>
**Inflazome <small>(Acq 2020)</small>
**GenMark Diagnostics <small>(Acq 2021)</small>
**TIB Molbiol <small>(Acq 2021)</small>
{{Tree list/end}}
{{hidden end}}

== Financial data ==
{| class="wikitable"
|+'''Financial data in CHF billions'''<ref>{{Cite web|url=https://www.wallstreet-online.de/aktien/roche-hldg-g-aktie/bilanz|title=Roche Holding Bilanz, Gewinn und Umsatz {{!}} Roche Holding Geschäftsbericht {{!}} 855167|website=wallstreet-online.de|access-date=2018-11-05}}</ref><ref>{{Cite web|last=MarketScreener|title=ROCHE HOLDING AG : Financial Data Forecasts Estimates and Expectations {{!}} ROG {{!}} CH0012032048 {{!}} MarketScreener|url=https://www.marketscreener.com/ROCHE-HOLDING-AG-9364975/financials/|access-date=2020-06-03|website=www.marketscreener.com|language=en}}</ref><ref>{{Cite web|last=GmbH|first=finanzen net|title=Roche Financials {{!}} Markets Insider|url=https://markets.businessinsider.com/stocks/roche/financials|access-date=2020-06-03|website=Business Insider}}</ref>
!Year
!2013
!2014
!2015
!2016
!2017
!2018
!2019
!2020
!2021
!2022
|-
|[[Finance:Revenue|Revenue]]
|46.780
|47.462
|48.145
|50.576
|53.299
|56.846
|63.751
|58.323
|62.801
|66.43
|-
|Net Income
|11.164
|9.332
|8.863
|9.576
|8.633
|10.865
|14.108
|15.068
|14.935
|13.53
|-
|Assets
|62.167
|75.641
|75.763
|76.819
|76.676
|78.517
|83.091
|86.138
|92.317
|88.15
|-
|Employees
|85,080
|88,509
|91,747
|94,052
|93,734
|94,442
|97,735
|101,238
|100,920
|103,613
|}

==Divisions==
Roche has two major divisions: Pharmaceuticals and Diagnostics.

Roche Diagnostics manufactures diagnostic equipment and reagents for research and medical diagnostic applications. Internally, it is organised into five major business areas: Roche Applied Science, Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics and Roche Tissue Diagnostics (Ventana). The main location for Roche Professional Diagnostics is in Rotkreuz, Switzerland.<ref name="FR21">{{cite web |url=https://assets.cwp.roche.com/f/126832/x/8df367bf68/fb21e.pdf |title=Financial Report 2021 |date=4 February 2022 |access-date=5 April 2022 |publisher=Roche Holding}}</ref>

All business areas except Roche Applied Science focus on health care applications, targeting either physicians, hospitals and clinics, or consumers. Applied Science targets research settings in academia and pharmaceutical and biotechnology industries.

==Products==
Hoffmann-La Roche develops drugs used for cancer treatment, against virus diseases and for treatment of metabolic diseases. The company is the world's largest spender in pharmaceutical R&D.<ref name="reuters17story">{{cite news|last1=Miller|first1=John|title=Roche touts Swiss-led R&D unit after years in Genentech's shadow|url=https://www.reuters.com/article/us-roche-swiss-research/roche-touts-swiss-led-rd-unit-after-years-in-genentechs-shadow-idUSKBN1ED0KA|access-date=19 December 2017|work=Reuters|date=19 December 2017}}</ref>

[[File:Tamiflu.JPG|thumb|Tamiflu box]]
Drugs produced by Roche include:{{update after|2020|1|8}}{{Original research inline|date=January 2020}}{{citation needed|date=January 2020}}
*Accutane/RoAccutane ([[Chemistry:Isotretinoin|isotretinoin]]), for severe (nodular) acne vulgaris - no longer sold under Accutane brand name but is still available as RoAccutane, other brand names and Isotretinoin generics.<ref>{{Cite news|title = Roche stops selling acne drug Accutane|url = https://www.reuters.com/article/us-roche-acne-idUSTRE55P53C20090626|work = Reuters|date = 2009-06-26|access-date = 2016-02-23}}</ref>
*Actemra/RoActemra ([[Chemistry:Tocilizumab|tocilizumab]]), for rheumatoid arthritis.
*Actimmune ([[Biology:Interferon gamma|interferon gamma]]), for chronic granulomatous disease, later sold to Connetics Corporation, then InterMune, after that Vidara Therapeutics and finally Horizon Pharma as of 2019.
*Activase ([[Medicine:Alteplase|alteplase]]), for heart attacks.
*Akynzeo (netupitant/palonosetron), for nausea and vomiting, licensed by Eisai Co. and Helsinn Therapeutics.
*Alecensa ([[Chemistry:Alectinib|alectinib]]), for ALK-positive non-small cell lung cancer.
*Aloxi ([[Chemistry:Palonosetron|palonosetron]]), for nausea and vomiting, licensed by Eisai Co. and Helsinn Therapeutics.
*[[Chemistry:Flumazenil|Anexate]] ([[Chemistry:Flumazenil|flumazenil]]), for the reversal of acute benzodiazepine effects.
*Aurorix ([[Biology:Moclobemide|moclobemide]]), for depression.
*Avastin ([[Chemistry:Bevacizumab|bevacizumab]]), for certain malignant tumours.
*Bactrim (trimethoprim/sulfamethoxazole), a sulphonamide antibacterial.
*[[Chemistry:Ibandronic acid|Boniva]]/Bonviva ([[Chemistry:Ibandronic acid|ibandronic acid]]), for the treatment of osteoporosis in postmenopausal women.
*Camleed ([[Chemistry:Enprostil|enprostil]]), for gastric ulcer prevention.
*Cardene ([[Chemistry:Nicardipine|nicardipine]]), for treatment of stable angina pectoris.
*Cathflo Activase ([[Medicine:Alteplase|alteplase]]), for heart attacks.
*Cellcept (mycophenolate mofetil), for transplant rejection.
*Cotellic ([[Chemistry:Cobimetinib|cobimetinib]]), for melanoma.
*Cymevene ([[Chemistry:Ganciclovir|ganciclovir]]), for cytomegalovirus infection.
*Dalmane/Dalmadorm ([[Chemistry:Flurazepam|flurazepam]]), for insomnia.
*Dilatrend ([[Chemistry:Carvedilol|carvedilol]]), for hypertension and congestive heart failure.
*Dormicum ([[Chemistry:Midazolam|midazolam]]), for insomnia and [[Medicine:Procedural sedation and analgesia|procedural sedation and analgesia]].
*Erivedge ([[Chemistry:Vismodegib|vismodegib]]), for basal-cell carcinoma.
*Esbriet ([[Chemistry:Pirfenidone|pirfenidone]]), for idiopathic pulmonary fibrosis.
*Fansidar (sulfadoxine/pyrimethamine), for malaria and toxoplasmosis.
*Fuzeon ([[Chemistry:Enfuvirtide|enfuvirtide]]), for [[Medicine:Salvage therapy|salvage therapy]] of HIV-1 infection.
*Gazyva ([[Chemistry:Obinutuzumab|obinutuzumab]]), for chronic lymphocytic leukaemia.
*Hemlibra ([[Chemistry:Emicizumab|emicizumab]]), for haemophilia A.
*Herceptin ([[Chemistry:Trastuzumab|trastuzumab]]), for HER-2 positive breast cancer.
*Hivid ([[Chemistry:Zalcitabine|zalcitabine]]), for HIV-1 infection, later discontinued in 2006.
*Inhibace ([[Chemistry:Cilazapril|cilazapril]]), for hypertension and congestive heart failure.
*Invirase ([[Chemistry:Saquinavir|saquinavir]]), for HIV-1 infection.
*Kadcyla ([[Chemistry:Trastuzumab emtansine|trastuzumab emtansine]]), for HER-2 positive breast cancer.
*Klonopin/Rivotril ([[Chemistry:Clonazepam|clonazepam]]), for epilepsy and anxiety disorders.
*Kytril ([[Chemistry:Granisetron|granisetron]]), for chemotherapy-induced nausea and vomiting, licensed by [[Company:GlaxoSmithKline|GlaxoSmithKline]].
*Lariam ([[Physics:Mefloquine|mefloquine]]), for malaria (both prevention and treatment).
*Lexotanil ([[Chemistry:Bromazepam|bromazepam]]), for anxiety disorders.
*Librax (Chlordiazepoxide/clidinium bromide), treating stomach ulcers, irritable bowel syndrome, or symptoms related to intestinal infection.
*Librium ([[Chemistry:Chlordiazepoxide|chlordiazepoxide]]), for anxiety disorders.
*Lucentis ([[Chemistry:Ranibizumab|ranibizumab]]), for wet age-related macular degeneration (AMD).
*Luxturna ([[Biology:Voretigene neparvovec|voretigene neparvovec]]), for [[Medicine:Leber's congenital amaurosis|Leber's congenital amaurosis]].
*MabThera ([[Chemistry:Rituximab|rituximab]]), for B-cell chronic lymphocytic leukaemia (and other haematological malignancies), non-Hodgkin lymphomas and rheumatoid arthritis.
*Madopar/Prolopa (levodopa/[[Chemistry:Benserazide|benserazide]]), for Parkinson's disease.
*Mircera (methoxy polyethylene glycol-epoetin beta), for anaemia associated with chronic kidney disease.
*Naprosyn ([[Chemistry:Naproxen|naproxen]]), an NSAID used for pain relief and arthritis treatment.
*Neulastim ([[Chemistry:Pegfilgrastim|pegfilgrastim]]), for neutropaenia.
*Neupogen ([[Chemistry:Filgrastim|filgrastim]]), for neutropaenia.
*Nutropin (somatropin), for growth hormone deficiency.
*Nutropin AQ (somatropin), for growth hormone deficiency.
*Nutropin Depot (somatropin), for growth hormone deficiency, later discontinued in 2004 and replaced by Nutropin AQ.
*Ocrevus ([[Chemistry:Ocrelizumab|ocrelizumab]]), for MS.
*[[Medicine:Peginterferon alfa-2a|Pegasys]], ([[Medicine:Peginterferon alfa-2a|peginterferon alfa-2a]]) for hepatitis B and C.
*Perjeta ([[Chemistry:Pertuzumab|pertuzumab]]), for HER-2 positive breast cancer.
*[[Chemistry:Polatuzumab vedotin|Polivy]] ([[Chemistry:Polatuzumab vedotin|polatuzumab vedotin]]), for diffuse large B-cell lymphoma.
*Protropin ([[Chemistry:Somatrem|somatrem]]), for growth hormone deficiency, later discontinued in 2004 in favor of its successor, Nutropin.
*Pulmozyme ([[Chemistry:Dornase alfa|dornase alfa]]), for the improvement of pulmonary function in cystic fibrosis.
*Raptiva ([[Biology:Efalizumab|efalizumab]]), for psoriasis, later withdrawn in 2009 due to the risk of PML.
*Recormon/NeoRecormon (epoetin beta), for anaemia.
*Rituxan ([[Chemistry:Rituximab|rituximab]]), for non-Hodgkin's lymphoma.
*Rocaltrol ([[Chemistry:Calcitriol|calcitriol]]), for osteoporosis and hypocalcaemia.
*Rocephin ([[Chemistry:Ceftriaxone|ceftriaxone]]), a broad-spectrum cephalosporin antibiotic.
*Roferon A ([[Medicine:Peginterferon alfa-2a|peginterferon alfa-2a]]), for some haematological malignancies (hairy cell leukaemia, chronic myelogenous leukaemia), certain solid tumours (including Kaposi's sarcoma), genital warts and chronic hepatitis C.
*Rohypnol ([[Chemistry:Flunitrazepam|flunitrazepam]]), for severe insomnia.
*Rozlytrek ([[Chemistry:Entrectinib|entrectinib]]), for ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumours.
*Soriatane/Neotigason ([[Chemistry:Acitretin|acitretin]]), for psoriasis.
*Tamiflu ([[Chemistry:Oseltamivir|oseltamivir]]), for influenza A and B (both treatment and prevention).
*Tarceva ([[Chemistry:Erlotinib|erlotinib]]), for various cancers.
*Tasmar ([[Chemistry:Tolcapone|tolcapone]]), for parkinson's disease, licensed by Mylan and [[Company:Bausch Health|Bausch Health]].
*Tecentriq ([[Chemistry:Atezolizumab|atezolizumab]]), for non-small cell lung cancer.
*TNKase (tenecteplase), for heart attacks.
*Toradol ([[Chemistry:Ketorolac|ketorolac]]), for pain management.
*Valcyte ([[Chemistry:Valganciclovir|valganciclovir]]), for cytomegalovirus infection.
*Valium ([[Chemistry:Diazepam|diazepam]]), for anxiety disorders, alcohol withdrawal, status epilepticus and other conditions.
*Venclexta ([[Chemistry:Venetoclax|venetoclax]]), for chronic lymphocytic leukaemia.
*[[Chemistry:Midazolam|Versed]] ([[Chemistry:Midazolam|midazolam]]), for insomnia and [[Medicine:Procedural sedation and analgesia|procedural sedation and analgesia]].
*Vesanoid ([[Chemistry:Tretinoin|tretinoin]]), for acute promyelocytic leukaemia.
*Viracept ([[Chemistry:Nelfinavir|nelfinavir]]), for HIV-1 infection, licensed by [[Company:Pfizer|Pfizer]] and [[Company:ViiV Healthcare|ViiV Healthcare]].
*Xeloda ([[Chemistry:Capecitabine|capecitabine]]), for breast and colorectal cancer.
*Xenical ([[Biology:Orlistat|orlistat]]), for obesity.
*Xofluza ([[Chemistry:Baloxavir marboxil|baloxavir marboxil]]), for influenza A and B (both treatment and prevention).
*Xolair ([[Chemistry:Omalizumab|omalizumab]]), for asthma.
*Zelboraf ([[Chemistry:Vemurafenib|vemurafenib]]), for late-stage V600E BRAF mutation-positive melanoma.
*Zenapax ([[Chemistry:Daclizumab|daclizumab]]), for the prevention of acute transplant rejection.

Diabetes management products under the Accu-Chek brand include [[Engineering:Glucose meter|blood glucose meters]], test strips and insulin pumps, as well as diabetes management software.

Other products include:

*[[Engineering:Cobas Mira|Cobas Mira]]

== Price-fixing conspiracy ==

Stanley Adams, Roche's World Product Manager in Basel, contacted the European Economic Community in 1973 with evidence that Roche had been breaking antitrust laws, engaging in [[Social:Price fixing|price fixing]] and market sharing for vitamins with its competitors. Roche was fined accordingly, but a bungle on the part of the EEC allowed the company to discover that it was Adams who had blown the whistle. He was arrested for unauthorised disclosure&nbsp;— an offence under Swiss law&nbsp;— and imprisoned. His wife, having learnt that he might face decades in jail, committed suicide.<ref name=observer>{{cite news | url=https://www.theguardian.com/business/2001/nov/25/businessofresearch.research | title=Blowing the final whistle | last = Mathiason | first = Nick| work=The Observer | date=25 November 2001 | access-date=30 September 2014}}</ref>

In 1999 the firm pleaded guilty to participation in a worldwide conspiracy to raise and fix prices for vitamins sold in the US and globally.  Hoffmann-La Roche paid $500 million in criminal fines to the United States.<ref name=observer/><ref>[http://www.corporatecrimereporter.com/top100.html#Annotated Corporate Crime Reporter]. Corporate Crime Reporter. Retrieved 2013-11-24.</ref><ref>{{cite journal|url=http://capcp.psu.edu/papers/cartelpriceannouncements.pdf|title=Cartel price announcements: The vitamins industry|year=2008|journal=International Journal of Industrial Organization|volume=26}}</ref>

==Collaborative research==
In addition to internal research and development activities F. Hoffmann-La Roche is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of [[Medicine:Pre-clinical development|non-clinical]] safety assessment is the InnoMed PredTox.<ref>{{Cite book| last1 = Mattes | first1 = William B.| chapter = Public Consortium Efforts in Toxicogenomics | doi = 10.1007/978-1-60327-048-9_11 | title = Essential Concepts in Toxicogenomics| editor1-last = Mendrick | editor1-first = Donna L.| editor2-last = Mattes | editor2-first = William B.| series = [[Biology:Methods in Molecular Biology|Methods in Molecular Biology]]| volume = 460 | pages = 221–238 | year = 2008 | isbn = 978-1-58829-638-2 | pmid = 18449490 }}</ref><ref name="InnoMed PredTox official project website">{{cite web|url=http://www.innomed-predtox.com/consortium/members/ |title=InnoMed PredTox Member Organizations |access-date=2008-08-25 |url-status=dead |archive-url=https://web.archive.org/web/20080926214522/http://www.innomed-predtox.com/consortium/members/ |archive-date=26 September 2008 |df=dmy }}</ref> The company is expanding its activities in joint research projects within the framework of the [[Medicine:Innovative Medicines Initiative|Innovative Medicines Initiative]] of EFPIA and the European Commission.<ref name="IMI Call Topics 2008">{{cite web|url=http://imi.europa.eu/docs/calls01_en.zip|title=IMI Call Topics 2008|last=Innovative Medicines Initiative|work=IMI-GB-018v2-24042008-CallTopics.pdf|publisher=European Commission|access-date=2008-08-25|archive-url=https://web.archive.org/web/20091015122459/http://imi.europa.eu/docs/calls01_en.zip|archive-date=15 October 2009|url-status=dead|df=dmy-all}}</ref>

==See also==
* List of pharmaceutical companies
* Pharmaceutical industry in Switzerland

==References==
{{Reflist|30em}}

==Further reading==
* Hans Conrad Peyer (1996) ''Roche – A Company History 1896–1996 '' Basel: Editiones Roche {{ISBN|3-907770-59-5}}

==External links==
* [https://diagnostics.roche.com/ Roche Diagnostics]



[[Category:Orphan drug companies]]

{{Sourceattribution|Roche|1}}